BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 21518026)

  • 1. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.
    Shivaprakash MR; Geertsen E; Chakrabarti A; Mouton JW; Meis JF
    Mycoses; 2011 Sep; 54(5):e583-9. PubMed ID: 21518026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
    Rudramurthy SM; Chakrabarti A; Geertsen E; Mouton JW; Meis JF
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):370-7. PubMed ID: 21937186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.
    Yamazaki T; Inagaki Y; Fujii T; Ohwada J; Tsukazaki M; Umeda I; Kobayashi K; Shimma N; Page MG; Arisawa M
    Int J Antimicrob Agents; 2010 Oct; 36(4):324-31. PubMed ID: 20674282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of five antifungal agents against 199 clinical and environmental isolates of Aspergillus flavus, an opportunistic fungal pathogen.
    Khodavaisy S; Badali H; Hashemi SJ; Aala F; Nazeri M; Nouripour-Sisakht S; Sorkherizi MS; Amirizad K; Aslani N; Rezaie S
    J Mycol Med; 2016 Jun; 26(2):116-121. PubMed ID: 26948143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
    Seifert H; Aurbach U; Stefanik D; Cornely O
    Antimicrob Agents Chemother; 2007 May; 51(5):1818-21. PubMed ID: 17307977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
    Shi JY; Xu YC; Shi Y; Lü HX; Liu Y; Zhao WS; Chen DM; Xi LY; Zhou X; Wang H; Guo LN
    Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Raffetin A; Courbin V; Jullien V; Dannaoui E
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038263
    [No Abstract]   [Full Text] [Related]  

  • 9. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species.
    Thompson GR; Wiederhold NP; Sutton DA; Fothergill A; Patterson TF
    J Antimicrob Chemother; 2009 Jul; 64(1):79-83. PubMed ID: 19406849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
    Espinel-Ingroff A
    Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular identification and antifungal susceptibility profile of Aspergillus flavus isolates recovered from clinical specimens in Kuwait.
    Al-Wathiqi F; Ahmad S; Khan Z
    BMC Infect Dis; 2013 Mar; 13():126. PubMed ID: 23496810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antifungal susceptibility of clinical and environmental isolates of Aspergillus fumigatus and Aspergillus flavus in Brazil.
    Bedin Denardi L; Hoch Dalla-Lana B; Pantella Kunz de Jesus F; Bittencourt Severo C; Morais Santurio J; Zanette RA; Hartz Alves S
    Braz J Infect Dis; 2018; 22(1):30-36. PubMed ID: 29172033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of environmental versus clinical strains of pathogenic Aspergillus.
    Araujo R; Pina-Vaz C; Rodrigues AG
    Int J Antimicrob Agents; 2007 Jan; 29(1):108-11. PubMed ID: 17189101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of isavuconazole MIC strips for susceptibility testing of Aspergillus and Scedosporium species.
    Trovato L; Scalia G; Palermo CI; Costanzo CM; Oliveri S
    Med Mycol; 2019 Jun; 57(4):429-433. PubMed ID: 30124992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterisation of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus.
    Krishnan-Natesan S; Chandrasekar PH; Alangaden GJ; Manavathu EK
    Int J Antimicrob Agents; 2008 Dec; 32(6):519-24. PubMed ID: 18775650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018.
    Messer SA; Carvalhaes CG; Castanheira M; Pfaller MA
    Diagn Microbiol Infect Dis; 2020 May; 97(1):115007. PubMed ID: 32081523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.
    Pfaller MA; Duncanson F; Messer SA; Moet GJ; Jones RN; Castanheira M
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5155-8. PubMed ID: 21844312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates.
    Astvad KMT; Hare RK; Arendrup MC
    Clin Microbiol Infect; 2017 Nov; 23(11):882-887. PubMed ID: 28373148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antifungal susceptibilities of Aspergillus spp. strains isolated from invasive aspergillosis cases].
    Gürcan S; Tikveşli M; Eryildiz C; Evci C; Ener B
    Mikrobiyol Bul; 2010 Apr; 44(2):273-8. PubMed ID: 20549962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro interactions of azoles and echinocandins against clinical strains of Aspergillus flavus.
    Denardi LB; Oliveira V; de Jesus FPK; Dalla-Lana BH; Santurio JM; Zanette RA; Alves SH
    Med Mycol; 2018 Nov; 56(8):1006-1011. PubMed ID: 29294129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.